Skip to main content

Bruce Alan Sullenger, PhD

Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine
Professor of Surgery
Associate Professor in Molecular Genetics and Microbiology
Professor of Pharmacology and Cancer Biology
Office: 1079 MSRB II, Box 103035, Durham, NC 27710
Campus Mail: DUMC Box 103035, Durham, NC 27710

The main focus of my translational research laboratory is to develop RNA based therapeutic agents for the potential treatment of a range of diseases. To this end, we have and will continue to take advantage of the fact that RNA is not just a passive carrier of genetic instructions inside of cells during the conversion of information from DNA to RNA to protein. Rather, RNA is an extremely versatile biological macromolecule. Certian RNAs can bind to specific protiens with high affinities, while others can for catalytic centers and perform enzymatic reactions. These facets of RNA coupled with the ease with which RNA can be manipulated in vitro make it a very powerful and unique therapeutic agent whose potential is largely untapped. Durring our endeavors, we plan to work closely with the members of the Molecular Therapeutics program as well as other faculty at the Duke University Medical Center to expedite the development and testing of these therapeutics.

The specific aims of my laboratory are:

1. To isolate and characterize RNA and DNA aptamers which block therapeutically relavent proteins such as those involved in cardiovascular diseases and immune modulation.

2. To develop RNA-based tumor targeting strategies for delivering siRNAs and miRNAs to tumor cells.

3. To reprogram cells using mRNA delivery.

4. To explore novel methods to control inflammation.

Education and Training

  • Ph.D., Cornell University, 1990

Selected Grants


Naqvi, I, Gunaratne, R, McDade, JE, Moreno, A, Rempel, RE, Rouse, DC, Herrera, SG, Pisetsky, DS, Lee, J, White, RR, and Sullenger, BA. "Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis." Molecular therapy : the journal of the American Society of Gene Therapy (February 23, 2018).

Full Text

Toulmé, J-J, Giangrande, P, Mayer, G, Suess, B, Ducongé, F, Sullenger, B, de Franciscis, V, Darfeuille, F, and Peyrin, E. "Aptamers in Bordeaux, 24–25 June 2016." Pharmaceuticals 10, no. 4 (December 2017): 14-14.

Full Text

Steen Burrell, K-A, Layzer, J, and Sullenger, BA. "A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release." Journal of thrombosis and haemostasis : JTH 15, no. 9 (September 2017): 1807-1817.

Full Text

Woodruff, RS, Ivanov, I, Verhamme, IM, Sun, M-F, Gailani, D, and Sullenger, BA. "Generation and characterization of aptamers targeting factor XIa." Thrombosis research 156 (August 2017): 134-141.

Full Text

Lee, J, Lee, Y, Xu, L, White, R, and Sullenger, BA. "Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs." Molecular therapy : the journal of the American Society of Gene Therapy 25, no. 6 (June 2017): 1295-1305.

Full Text

Lee, J, Jackman, JG, Kwun, J, Manook, M, Moreno, A, Elster, EA, Kirk, AD, Leong, KW, and Sullenger, BA. "Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis." Biomaterials 120 (March 2017): 94-102.

Full Text

Nimjee, SM, White, RR, Becker, RC, and Sullenger, BA. "Aptamers as Therapeutics." Annual review of pharmacology and toxicology 57 (January 2017): 61-79. (Review)

Full Text

Plautz, WE, Layzer, J, Sullenger, BA, and Majumder, R. "Aptamer Mediated Inhibition of Protein S." December 2, 2016.


Kim, J, Naqvi, I, Nag, UP, Leraas, HJ, Otto, JC, Borst, AJ, Hill, KD, Fleming, GA, Sullenger, BA, and Tracy, ET. "Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants." December 2, 2016.


Gunaratne, R, Frederiksen, J, Thalji, NK, Ho, MD, Arepally, GM, Camire, RM, and Sullenger, BA. "RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit." December 2, 2016.